These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38630999)

  • 1. Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    Emanuel EJ; Dellgren JL; McCoy MS; Persad G
    N Engl J Med; 2024 May; 390(20):1839-1842. PubMed ID: 38630999
    [No Abstract]   [Full Text] [Related]  

  • 2. Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023.
    Lee JM; Sharifi M; Oshman L; Griauzde DH; Chua KP
    JAMA; 2024 Jun; 331(23):2041-2043. PubMed ID: 38776113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable.
    Harris E
    JAMA; 2024 Jul; 332(1):8. PubMed ID: 38848082
    [No Abstract]   [Full Text] [Related]  

  • 4. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery Device Patents on GLP-1 Receptor Agonists.
    Alhiary R; Gabriele S; Kesselheim AS; Tu SS; Feldman WB
    JAMA; 2024 Mar; 331(9):794-796. PubMed ID: 38315473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.
    Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W
    Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How May GIP Enhance the Therapeutic Efficacy of GLP-1?
    Samms RJ; Coghlan MP; Sloop KW
    Trends Endocrinol Metab; 2020 Jun; 31(6):410-421. PubMed ID: 32396843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin therapy for diabetes mellitus type 2.
    Holst JJ
    Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):2-10. PubMed ID: 31815785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a novel long-acting dual GLP-1/GIP receptor agonist.
    Dong Y; Zhang J; Xu H; Shen H; Lu Q; Feng J; Cai Z
    Bioorg Med Chem; 2024 Feb; 100():117630. PubMed ID: 38330849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide.
    Azizi Z; Rodriguez F; Assimes TL
    Circulation; 2024 Jul; 150(3):171-173. PubMed ID: 39008562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity.
    Usui R; Yabe D; Seino Y
    J Diabetes Investig; 2019 Jul; 10(4):902-905. PubMed ID: 30637966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.
    Scheen AJ
    Ann Endocrinol (Paris); 2023 Apr; 84(2):316-321. PubMed ID: 36639119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.
    Holst JJ; Rosenkilde MM
    J Clin Endocrinol Metab; 2020 Aug; 105(8):e2710-6. PubMed ID: 32459834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the glucagon receptor family for diabetes and obesity therapy.
    Cho YM; Merchant CE; Kieffer TJ
    Pharmacol Ther; 2012 Sep; 135(3):247-78. PubMed ID: 22659620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?
    Smits MM; Holst JJ
    Diabetes Metab Res Rev; 2023 Nov; 39(8):e3699. PubMed ID: 37485788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Out of stock: A brief clinical reference for rough equivalency of glucagon-like peptide-1 (GLP-1) ± glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes.
    Perreault L; Bergman BC
    J Diabetes; 2024 Jun; 16(6):e13505. PubMed ID: 37986549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.